|
1
|
Zuehlke RL: Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica. 148:90–92. 1974.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Miller KK, Gorcey L and McLellan BN: Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 71:787–794. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Twelves C, Wong A, Nowacki MP, Abt M, Burris H III, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 352:2696–2704. 2005.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Heo YS, Chang HM, Kim TW, Ryu MH, Ahn JH, Kim SB, Lee JS, Kim WK, Cho HK and Kang YK: Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. J Clin Pharmacol. 44:1166–1172. 2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Yokokawa T, Kawakami K, Mae Y, Sugita K, Watanabe H, Suzuki K, Suenaga M, Mizunuma N, Yamaguchi T and Hama T: Risk factors exacerbating hand-foot skin reaction induced by capecitabine plus oxaliplatin with or without bevacizumab therapy. Ann Pharmacother. 49:1120–1124. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Macedo LT, Lima JP, dos Santos LV and Sasse AD: Prevention strategies for chemotherapy-induced hand-foot syndrome: A systematic review and meta-analysis of prospective randomized trials. Support Care Cancer. 22:1585–1593. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chen M, Chen J, Peng X, Xu Z, Shao J, Zhu Y, Li G, Zhu H, Yang B, Luo P and He Q: The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome. Environ Toxicol Pharmacol. 49:81–88. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Martschick A, Sehouli J, Patzelt A, Richter H, Jacobi U, Oskay-Ozcelik G, Sterry W and Lademann J: The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res. 29:2307–2313. 2009.PubMed/NCBI
|
|
9
|
Saif MW, Elfiky A and Diasio R: Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Clin Colorectal Cancer. 6:219–223. 2006.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hoesly FJ, Baker SG, Gunawardane ND and Cotliar JA: Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: Case report and review of the literature. Arch Dermatol. 147:1418–1423. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lin E, Morris JS and Ayers GD: Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park). 16 (Suppl 14):S31–S37. 2002.PubMed/NCBI
|
|
12
|
Zhang RX, Wu XJ, Wan DS, Lu ZH, Kong LH, Pan ZZ and Chen G: Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: Result of a single-center, prospective randomized phase III trial. Ann Oncol. 23:1348–1353. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Petersen PB, Mikkelsen KL, Lauritzen JB and Krogsgaard MR: Risk factors for post-treatment complex regional pain syndrome (CRPS): An analysis of 647 cases of CRPS from the Danish patient compensation association. Pain Pract. 18:341–349. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Galer BS, Bruehl S and Harden RN: IASP diagnostic criteria for complex regional pain syndrome: A preliminary empirical validation study. International association for the study of pain. Clin J Pain. 14:48–54. 1998.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sumitani M, Shibata M, Sakaue G and Mashimo M: Japanese CRPS Research Group. Development of comprehensive diagnostic criteria for complex regional pain syndrome in the Japanese population. Pain. 150:243–249. 2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Almeida da Cruz L, Hoff PM, Ferrari CL and Riechelmann RS: Unilateral hand-foot syndrome: Does it take sides? Case report and literature review. Clin Colorectal Cancer. 11:82–84. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Disel U, Gürkut O, Abali H, Kaleağasi H, Mertsoylu H, Ozyilkan O and Saif MW: Unilateral hand-foot syndrome: An extraordinary side effect of capecitabine. Cutan Ocul Toxicol. 29:140–142. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Matsuda S, Koketsu H, Hayakawa M and Nagata N: Unilateral capecitabine-related hand-foot syndrome. Intern Med. 54(2779)2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Huang MD, Fuss H, Lademann J, Florek S, Patzelt A, Meinke MC and Jung S: Detection of capecitabine (Xeloda®) on the skin surface after oral administration. J Biomed Opt. 21(47002)2016.PubMed/NCBI View Article : Google Scholar
|
